Introduction and Fraud Allegations

Soleno Therapeutics (NASDAQ: SLNO), a biotech company focused on rare diseases, is facing a securities fraud class action lawsuit that investors need to know about. The lawsuit – with a lead plaintiff deadline of May 5, 2026 – alleges Soleno failed to disclose significant safety issues in its Phase 3 trials for DCCR (brand name VYKAT™ XR) (nationaltoday.com) (www.prnewswire.com). Specifically, the complaint claims Soleno “minimized, mischaracterized, and failed to disclose” evidence of excessive fluid retention in patients using DCCR, which could signal serious heart-related side effects (nationaltoday.com). By underplaying these risks, Soleno allegedly misled investors about DCCR’s true safety profile and commercial viability. On November 5, 2025, the company revealed “disappointing information” about DCCR that triggered a 26% stock drop in one day (www.prnewswire.com). This report, and earlier revelations, suggest that shareholders may have been kept in the dark about material risks – hence the urgency for affected investors to act by the legal deadline.

Don't wait — first dividend checks could arrive any day.

Get the concise guide to start collecting royalty checks now.

Get Instant Access
✕

Company Background: One Drug, Big Impact

Soleno Therapeutics is essentially a one-product company. It received FDA approval on March 26, 2025 for DCCR (VYKAT XR), the first and only approved therapy to treat hyperphagia (extreme appetite) in patients with Prader-Willi syndrome (seekingalpha.com). Soleno launched VYKAT XR in the U.S. in Q2 2025 and saw rapid initial uptake: by Q3 2025, they had 1,043 patient start forms and 764 patients on therapy, driving $66.0 million in quarterly revenue (seekingalpha.com) (seekingalpha.com). Management touted a “compelling efficacy and safety profile” for VYKAT XR, highlighting that some patients have been on treatment for over six years (seekingalpha.com). Indeed, through Q4 2025, the company achieved 12% penetration of the U.S. addressable PWS market (1,250 total patient start forms) within nine months of launch (www.globenewswire.com) (www.globenewswire.com). This fast start even turned Soleno profitable in 2025, a rare feat for a first-year biotech launch. Full-year 2025 revenues hit $190.4 million, with net income of $20.9 million (www.globenewswire.com) (www.globenewswire.com). However, as we’ll see, cracks began to appear beneath this growth story.

Dividend Policy & Shareholder Returns

Like most emerging biotechs, Soleno does not pay any dividend – all earnings are reinvested into the business. Yahoo Finance confirms no dividend or yield for SLNO stock (finance.yahoo.com). Instead of dividends, Soleno rewarded shareholders via share buybacks once cash started pouring in. In November 2025, amid share-price volatility, the company authorized a $100 million accelerated share repurchase (ASR) program (www.globenewswire.com). This sizable buyback (funded by Soleno’s ample cash reserves) signaled management’s confidence in the company’s value. Going forward, investors should not expect dividend income from SLNO; any shareholder return will likely come through stock price appreciation (or further buybacks) rather than cash payouts.

Financial Leverage and Debt Maturities

Soleno’s balance sheet is strong, with minimal debt relative to cash. In late 2024, the company secured a credit facility with Oxford Finance, drawing an initial $50 million term loan (investors.soleno.life). This debt carries interest at roughly SOFR + 5.5% and features an interest-only period of 48 months, with a five-year maturity (extended by 12 months if performance milestones are met) (investors.soleno.life). In other words, no principal repayment is due until at least late 2029, giving Soleno plenty of breathing room to grow the business. As of year-end 2025, long-term debt stood at ~$50 million (seekingalpha.com), unchanged from 2024, while cash and investments were over $500 million. The company’s net leverage is effectively zero (cash exceeds debt), indicating a very conservative capital structure. Soleno did assume a contingent liability of ~$19 million related to its acquisition of Essentialis (the originator of DCCR) (seekingalpha.com), but this likely corresponds to milestone payments owed upon DCCR’s success. Overall, Soleno’s debt profile is low-risk: the sole loan is long-dated and interest-only, and huge cash reserves could repay it easily if needed.

Liquidity and Coverage

Thanks to the successful launch of VYKAT XR, Soleno has rapidly transformed into a cash-generating entity. In Q4 2025 alone, the company produced $48.7 million of operating cash flow (www.globenewswire.com) (finsee.ai), reflecting high margins on its rare-disease drug. Gross margins are nearly 98–100%, since VYKAT XR is a once-daily pill with low manufacturing cost (finsee.ai). Meanwhile, operating expenses grew modestly relative to revenue, yielding a 47% net profit margin in Q4 (finsee.ai). This means Soleno’s earnings easily cover its fixed charges. Annual interest on the $50 million debt is roughly $5 million, a trivial outlay given the company’s cash flow. Indeed, Soleno’s interest coverage is extremely robust – in Q4, operating cash flow was almost 10× the annual interest expense. With $506 million in cash on hand (www.globenewswire.com), Soleno is well-equipped to fund R&D, potential expansions, and any legal costs without liquidity strain. In short, near-term financial risk from debt or cash burn is low, a notable positive for shareholders.

Valuation and Stock Performance

Soleno’s market valuation reflects both its commercial progress and future growth expectations. At a recent share price around $49, Soleno’s market capitalization is roughly $2.6 billion (53.7 million shares) and enterprise value about $2.1 billion after cash. That equates to approximately 11× 2025 sales, a rich price-to-revenue multiple for a single-product pharma. On a profit basis, the stock trades at an elevated earnings multiple (125× 2025 EPS) since profitability only just emerged. Investors are essentially pricing in continued high growth and expansion into new markets. The stock’s ride has been volatile: SLNO surged on FDA approval and early sales, then plunged nearly 40% from mid-August to early November 2025 as concerns surfaced (www.prnewswire.com). Notably, on November 5, 2025 – after Q3 results revealed slower patient uptake – the stock fell 26% in one day (www.prnewswire.com). This volatility underscores how sensitive Soleno’s valuation is to news on DCCR’s outlook. Peers are hard to find (Soleno is first-to-market in PWS), but generally, orphan drug companies with strong launch trajectories can command high multiples. The key question is whether Soleno can maintain its growth to justify the valuation. At ~11× sales, investors are assuming VYKAT XR will reach many more patients (and possibly new indications or geographies). Any sign of plateauing U.S. demand or safety hurdles (see below) could pressure this premium valuation.

Risks, Red Flags, and Litigation

Despite Soleno’s financial successes, significant risks have come to light that cast a shadow on its growth story:

– Safety Concerns & Lawsuit: The class action lawsuit alleges Soleno concealed important safety data from its DCCR trials. In particular, trial patients were reportedly experiencing fluid retention issues (swelling, edema) that could lead to serious cardiac problems (nationaltoday.com). If true, DCCR may pose greater health risks than investors were led to believe, undermining its adoption. Soleno’s executives had repeatedly claimed DCCR’s safety/efficacy profile was favorable, so these revelations raise trust issues. The lawsuit claims these omissions mean DCCR’s commercial prospects were overstated, since undisclosed risks (like high discontinuation rates or doctor reluctance) could limit long-term sales (nationaltoday.com) (www.prnewswire.com).

– Short-Seller Allegations: In August 2025, activist short-seller Scorpion Capital published a damning report on Soleno (www.prnewswire.com). Scorpion highlighted a “rapid pile-up of reports of children hospitalized for potential heart failure” shortly after VYKAT XR’s launch (www.prnewswire.com). This suggested DCCR’s fluid-retention side effects might be severe enough to cause cardiac failure in some PWS patients – a dire outcome not clearly disclosed. Scorpion warned that VYKAT XR could even face withdrawal from the market or a plunge in new prescriptions if such safety events continued (www.prnewswire.com). The short report also accused Soleno of pumping its launch metrics: it alleged the company’s early patient uptake was “hocus-pocus”, overly reliant on a single clinician in Florida who was a lead trial investigator (www.prnewswire.com). That physician allegedly drove an outsized number of patient enrollments (“invisible hand fueling initial start forms” (www.prnewswire.com)), calling into question how organic the demand truly was. Even more troubling, Scorpion scrutinized scientific papers co-authored by this doctor and found “red flags for data integrity” – irregularities suggesting the DCCR trial data and Soleno’s FDA submission might not fully adhere to scientific standards (www.prnewswire.com). These allegations, if validated, point to serious red flags in Soleno’s trial conduct and launch strategy.

– Management’s Acknowledgment: Importantly, Soleno’s own management conceded some of these issues on the Q3 2025 earnings call. Executives admitted that “we did see a disruption in our launch trajectory in the wake of a short seller report… mostly in the form of a lower number of start forms and increased discontinuations for non-serious adverse events.” (www.prnewswire.com) In other words, after the Scorpion report in August, fewer new patients started VYKAT XR and more existing patients dropped off (even if side effects were “non-serious” like manageable edema). This matches what the data showed: new patient start forms fell dramatically by Q4 2025 (from 646 in Q2, to 397 in Q3, to just 207 in Q4) (finsee.ai) (finsee.ai). Soleno also disclosed an overall 12% adverse event discontinuation rate by year-end (investors.soleno.life) (investors.soleno.life) – meaning roughly one in eight patients quit VYKAT XR due to side effects. These figures contradict the earlier rosy narrative and confirm that safety/tolerability issues are impacting growth. The fact that a short report forced this admission indicates Soleno may not have been fully transparent initially. Additionally, it came to light that there was a patient death in the period following launch (details are sparse, but this was subsequently disclosed to investors) (simplywall.st). Any death in a fragile patient population like PWS is scrutinized, even if causality is unclear.

– Single-Product Dependency: Beyond the lawsuit-specific claims, Soleno faces the classic risk of a one-product company. Virtually all revenue comes from VYKAT XR in PWS, so any setback – safety alert, new competing therapy, or regulatory action – would be devastating. Investors are effectively “all in” on DCCR’s success. The lawsuit’s allegations heighten this risk: if regulators re-evaluate DCCR’s safety or if physicians grow hesitant to prescribe it, Soleno has no other commercialized drugs to fall back on. The company does plan to seek approval in Europe and explore DCCR in additional rare diseases (www.globenewswire.com), but those efforts are early-stage. Until another pipeline candidate emerges, Soleno’s fortunes rise and fall with DCCR.

– Reputation and Regulatory Risk: The overhang of a fraud lawsuit and short-seller accusations could have lasting effects. At minimum, management will be distracted by legal defense and may adopt extra caution in communications. In a worse scenario, the FDA or EMA might impose new requirements (e.g. stronger warning labels, post-market studies) if they believe certain side effects were underreported. If the data integrity concerns gain traction, there’s even a risk (albeit very low) of regulatory inquiry into the trial’s validity. Such outcomes could slow down prescriptions and payer acceptance, as trust is paramount for a new therapy in a vulnerable pediatric population (nationaltoday.com) (simplywall.st).

In sum, Soleno’s initial success with VYKAT XR is now tempered by serious red flags. The fraud claims amplify the existing risks of safety issues and concentrated revenue. Current shareholders should monitor these developments closely – the legal process may unearth information that either validates or dispels the allegations. For now, caution is warranted given the uncertainties around DCCR’s true risk/benefit profile.

Open Questions for Shareholders

As Soleno navigates this critical period, several open questions remain:

– What Will Come of the Class Action? – Will court proceedings (or a settlement) bring to light new facts about what Soleno knew regarding DCCR’s safety? Any finding of improper disclosure could lead to compliance changes, higher legal costs, or oversight that might impact operations (simplywall.st). Conversely, if the claims are disproven, it could restore confidence – but that resolution is far off. Investors are left to speculate how damaging (or not) the fraud allegations truly are.

– Could Regulators or Insurers React? – If reports of serious adverse events (e.g. cardiac issues from fluid retention) continue, will the FDA step in with additional guidance or a safety alert? Already, dropout rates and hospitalization reports have caught attention (www.prnewswire.com). It’s unclear if any formal regulatory action is on the horizon. Similarly, will insurers/payers remain supportive if questions linger about VYKAT XR’s risk profile? Soleno boasts broad coverage now (185 million lives) (finsee.ai); maintaining that depends on sustained confidence in the drug’s safety and effectiveness.

– Can Growth be Re-Ignited? – A critical issue is whether Soleno can reaccelerate patient uptake after the recent slowdown. Management insists leading indicators are still “positive,” but Q4’s sharp drop in new starts tells a different story (finsee.ai). Is the deceleration temporary – perhaps due to the short-seller scare – or a sign that most early adopters are onboard and it will be harder to grow from here? The company will need to rebuild momentum through physician outreach and possibly new data (or real-world evidence) to prove DCCR’s benefits outweigh its side effects. How Q1 and Q2 2026 patient metrics trend will be very telling.

– How Will Europe and Pipeline Expansion Play Out? – Soleno is pursuing EU approval for DCCR (an application is under review in 2026) and exploring DCCR in other rare conditions (www.globenewswire.com). These are potential growth avenues, but open questions abound: Will European regulators have additional safety reservations given the U.S. experience? Can Soleno replicate its U.S. commercial success abroad, especially if the safety narrative follows them? And in other indications, can DCCR demonstrate efficacy? Until there’s clarity, geographic and pipeline expansion remain hopeful, not guaranteed.

– Is Management Trustworthy? – Finally, shareholders must ask whether Soleno’s management has been fully transparent. The lawsuit essentially accuses them of lacking candor about problems in the clinical program (www.prnewswire.com). The eventual outcomes (be it in court or in how the company communicates going forward) will answer this. If trust can be rebuilt – for instance, by proactively disclosing data and addressing concerns – Soleno may put these challenges behind it. If not, continued skepticism from analysts, investors, and doctors could weigh on the stock.

Bottom Line: Soleno Therapeutics delivered an impressive commercial launch in 2025, but it now faces a credibility test. Shareholders should stay alert to new disclosures or developments related to the fraud claims and DCCR’s safety. The coming months will be crucial in determining whether VYKAT XR’s growth trajectory resumes or stalls out under these clouds. With the class action lead plaintiff deadline looming (May 5, 2026) (www.prnewswire.com), investors with large losses have an immediate decision – but all SLNO shareholders have a stake in how these unresolved questions are answered in 2026 and beyond. Each risk factor and open question noted here warrants close monitoring as the Soleno story unfolds.

For informational purposes only; not investment advice.